Chao Chen

Dr. Chao Chen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
YWYi Wang
Yi Wang
JWJia Wang
Jia Wang
CCChao Chen
Chao Chen
LSLianhui Song
Lianhui Song
ZWZu-Li Wang
Zu-Li Wang
DYDong Yi
Dong Yi
Visible-light photoredox catalyzed 1,2-arylalkylation of alkenes with quinoxalin-2(1H)-ones and malonic esters has been developed through direct C(sp2)–H/C(sp3)–H functionalization under mild conditions.

29 October 2025 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
KZKai Zheng
Kai Zheng
CCChao Chen
Chao Chen
HXHao Xu
Hao Xu
JMJiangang Mao
Jiangang Mao
CSChao Shen
Chao Shen

30 January 2024 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
JSJiabin Shen
Jiabin Shen
YYYong Yang
Yong Yang
CCChao Chen
Chao Chen
HXHao Xu
Hao Xu
CSChao Shen
Chao Shen
PZPengfei Zhang
Pengfei Zhang
This study describes an efficient and green approach for the synthesis of potentially bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-ones with appreciable functional group tolerance and a wide substrate scope.

27 January 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
LSLiwei Shu
Liwei Shu
LRLulu Ren
Lulu Ren
YWYuchen Wang
Yuchen Wang
TFTao Fang
Tao Fang
ZYZhijian Ye
Zhijian Ye
WHWang Hangxiang
Wang Hangxiang
Niacin-ligated platinum(IV)–ruthenium(II) chimeric complexes (PtRu 1–4) have been synthesized and evaluated for their antitumor performance. Using the optimal complex, PtRu-1, we show that this water-soluble chimeric prodrug not only potently inhibits the metastasis and proliferation of tumor cells but also has an unexpectedly higher safety margin in animals compared with the traditionally-used, clinically approved drug cisplatin.

28 January 2020 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
CCChao Chen
Chao Chen
LZLiqian Zhou
Liqian Zhou
BXBinbin Xie
Binbin Xie
YWYuchen Wang
Yuchen Wang
LRLulu Ren
Lulu Ren
WHWang Hangxiang
Wang Hangxiang
In this study, we designed and synthesized four novel multi-nuclear silver complexes (1–4) coordinated with pyrazole- or pyridine-functionalized N-heterocyclic carbene (NHC) ligands. The crystal structures of the silver–NHC complexes were confirmed by X-ray diffraction analysis. In vitro assays showed that the silver–NHC complexes effectively killed a broad range of cancer cells after short-term drug exposure, serving as fast-acting cytotoxic agents. Of note, in cisplatin-resistant A549 cancer cells, the silver complexes were not cross-resistant with the clinically used cisplatin agent. Detailed mechanistic studies revealed that complex 2 triggered caspase-independent cell necrosis associated with intracellular reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP) depletion. By exploiting a facile nano-assembly process, silver–NHC complexes 1, 2 and 4 were successfully integrated into the hydrophobic cores of amphiphilic matrices (DSPE-PEG2K), enabling systemic injection. The silver complex-loaded nanotherapeutics (1-NPs, 2-NPs, and 4-NPs) showed high safety margins with reduced systemic drug toxicities relative to cisplatin in animals. Furthermore, in a xenograft model of human colorectal cancer, the administration of the nanotherapeutics resulted in a marked inhibition of tumor progression.

18 January 2017 in European Journal of Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
CCChao Chen
Chao Chen
SNShengliang Ni
Shengliang Ni
QZQing Zheng
Qing Zheng
MYMeifang Yu
Meifang Yu
WHWang Hangxiang
Wang Hangxiang